Emirates Drug Establishment Reviews Key Achievements And Outlines Future Plans For 2024-2026

The Emirates Drug Establishment (EDE) Board of Directors concluded its 2024 annual meetings, reviewing achievements and assessing strategic goals for 2024-2026. The board focused on innovation and sustainability in the medical and pharmaceutical sectors, aiming to enhance operational and research capabilities. This aligns with EDE's mission to drive progress in these critical areas.

Chaired by Dr. Thani bin Ahmed Al Zeyoudi, Minister of State for Foreign Trade, the meeting included key figures like Dr. Maha Taysir Barakat, Vice Chairman, and Dr. Fatima Mohammed Hilal Al Kaabi, Director-General. Other board members present were Dr. Essa Abdulfattah Kazim, Badr Salim Al Olama, Dr. Amer Ahmed Sharif, Dr. Farhan Malak, and Professor Chris Evans.

Dr. Al Zeyoudi highlighted EDE's role in achieving UAE's strategic objectives by promoting innovation and sustainability within the medical sector. He remarked on the importance of these industries as "fundamental pillars ensuring the sustainability of our healthcare system." He emphasised EDE's commitment to developing advanced solutions and forming strategic partnerships to position the UAE as a leader in pharmaceutical innovation.

Dr. Al Zeyoudi further noted that investing in modern technologies enhances EDE's capacity to address future challenges while creating solutions that sustain healthcare systems. The focus is on leveraging cutting-edge technologies to improve manufacturing processes and distribution efficiency.

The board also discussed fostering international cooperation and attracting investments in research and development. This supports the UAE's vision of becoming a global hub for medical innovation. Plans include developing innovative medical products and updating regulatory frameworks to ensure pharmaceutical security.

Dr. Al Kaabi emphasised EDE's dedication to executing strategic plans that meet ambitious goals. She stated, "We've made great progress in advancing our structure and strengthening research partnerships that would help improve the quality of life for our community." These efforts contribute significantly to sustainable economic growth.

Regulatory Frameworks and Quality Standards

The meeting explored strategies for establishing regulatory frameworks to advance pharmaceutical research and scientific studies. Emphasis was placed on implementing international quality standards within the industry to ensure safety and efficacy.

EDE aims to adopt advanced technologies like artificial intelligence to upgrade processes, accelerate innovation, and deliver sustainable health solutions. This approach is crucial for maintaining high standards in manufacturing and distribution while supporting national health objectives.

The discussions underscored EDE's commitment to enhancing its capabilities through strategic initiatives aimed at fostering growth in the medical sector. By prioritising innovation, collaboration, and technology adoption, EDE seeks to strengthen its position as a leader in pharmaceutical advancements globally.

With inputs from WAM